Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric Cancer

NCT ID: NCT03276156

Last Updated: 2017-09-08

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-02-23
• Study Completion Date: 2018-02-22

Brief Summary

The purpose of this study is to determine the maximum tolerated dose (MTD)and safety of Apatinib combined with S-1 as Second-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma.

Conditions

Gastric Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Apatinib plus S-1

Apatinib (425/500/675/750mg,qd,p.o.) concomitantly with S-1 (80mg to 120 mg, qd,days1-14, q3w, p.o.)

Group Type: EXPERIMENTAL

Apatinib plus S-1

Intervention Type: DRUG

Drug:Apatinib (425 mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (500 mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (675mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (750 mg/d) + S-1 (80mg to 120 mg);

Interventions

Apatinib plus S-1

Drug:Apatinib (425 mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (500 mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (675mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (750 mg/d) + S-1 (80mg to 120 mg);

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Fully informed consent prior to any specific research procedure.

2. Adult patients, aged ≥18 years;

3. Imaging test confirmed the progression after first-line treatment of advanced gastric adenocarcinoma or Gastroesophageal Junction Adenocarcinoma.

• S-1 was not used in the first-line treatment
• If patient relapse in 6 months after adjuvant chemotherapy or neoadjuvant chemotherapy, the adjuvant chemotherapy or neoadjuvant chemotherapy was regarded as the first-line treatment.

4. Adjuvant chemotherapy or neoadjuvant chemotherapy was allowed if the first-line treatment started beyond 6 months after the end of previous treatment.

5. During the research ,patient should be willing and be able to follow the process treatment ,follow up and tests.

6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1.

7. Survival expectation ≥ 16 weeks from the planned first dosing .

8. During the 28 days prior to the first dosing, hematological, biochemical and Organ Functions:HB ≥ 9.0 g/dL, ANC ≥ 1.5×109/L,WBC>3×109/L， PLT ≥ 100×109/L, BIL < 1.5×ULN, ALT or AST < 2.5×ULN (or < 5×ULN in patients with liver metastases), Serum Cr ≤ 1.5×ULN;

9. Lesions ,measurable and/or unmeasurable,at least one,can be assessed by imaging during the baseline and follow-up measurement.

• Localized mass in gastric or Gastroesophageal Junction belongs to unmeasurable Lesions.

10. Women, those postmenopausal or of child-bearing age, but the pregnancy test results (serum or urine) within 28 days before treatment is negative, and the results should be confirmed in day 1 of the treatment.

• Postmenopausal women are defined as :woman's menstrual periods have ceased for 1 year or longer after exogenous hormone therapy;
• Women, aged>50years,serum LH and FSH level show a postmenopause;
• Woman has radiation induced ovarian failure,and gone without a period for over 12 consecutive months;
• Woman has chemotherapy-induced menopause and gone without a period for over 12 consecutive months;
• sterilization operation( hysterectomy or bilateral oophorectomy)

Exclusion Criteria

1. Has participated in another clinical trial in progress.

2. Has received more than one chemotherapy regimens after disease progression(except for those who has receiced adjuvant chemotherapy or neoadjuvant chemotherapy 6 months or longer)

3. Previous therapy with S-1

4. Has received VEGFR inhibitor, such as Sorafenib,Sunitinib .

5. Has another primary tumor,but adequately treated non-melanoma skin cancer , effectively treated carcinoma in situ of cervix and other well handled cancer over 5 years were not covered.

6. Has difficulty in swallowing

7. Has taken experimental drugs within 14 days before randomly assign.( For different drug characteristics, the interval can be longer)

8. History of any chemotherapy, radiotherapy,the last administration should finish within 3 weeks prior to trial first drug administration( For different drug characteristics, the interval can be longer). If steady dose of diphosphate or denosumab is necessary for the treatment of bone metastases,the administration should start 3-4weeks prior to the study .

9. Patients with poor-controlled arterial hypertension (systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mm Hg) despite standard medical management; Coronary heart disease greater than Class I, arrhythmia greater than Class I (including QT interval prolongation, for man > 450 ms, for woman > 470 ms), and cardiac dysfunction greater than Class I;

10. Has persistent toxicity (exclude alopecia )of previous treatment ,CTCAE>1.

11. Has intestinal obstruction or upper gastrointestinal hemorrhage(CTCAE 3 or 4) within 4 weeks prior to randomly assign.

12. Abnormal coagulation function (INR > 1.5×ULN, APTT > 1.5×ULN), with tendency of bleed;

13. Has symptom of brain metastases and the tendency out of control,but imaging confirmed is not required.If steady dose of Glucocorticoid is necessary for the treatment,the administration should be started >4weeks prior to the study . Patients with spinal cord compression received definite treatment and the situation had been proven stable in 28days .

14. Has surgery within 2 weeks prior to the study. Eligible patients should recovered from any major surgery.

15. Subjects that are unable to swallow tablets, chronic diarrhea ,or intestinal obstruction;

16. Subjects with a clear tendency of gastrointestinal bleeding;

17. Pregnant or lactating women;

18. Other conditions regimented at investigators' discretion.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

Sponsor Role: collaborator

Zhejiang Cancer Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China

Site Status: RECRUITING

Countries

China

Central Contacts

Haijun Zhong

Role: CONTACT

ZHJ1712@aliyun.com

0571-88122058

Other Identifiers

Ahead-G001

Identifier Type: -

Identifier Source: org_study_id